Ireland
--:--IST
Starting soon Not applicable

Effect of Systematic and Sequential Leg Elevation on Cardiac Output in Healthy Volunteers

NCT07860515 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-10-10
Last updated
2026-10-06

Condition(s) studied

Healthy AdultCardiac OutputHemodynamicPassive Leg Raising

Investigational drug(s) / intervention(s)

Passive Leg RaisingNon-Invasive Ventilation

Passive Leg Raising: Passive leg raising is performed using an electrically operated hospital bed to move participants from a semi-recumbent position (30° trunk elevation) to a position with the trunk horizontal and legs elevated at 45°. Each maneuver lasts 10 minutes and is repeated six times at hourly intervals.

Non-Invasive Ventilation: Non-invasive ventilation is delivered via an oronasal mask using a critical care ventilator. NIV is applied for 5 minutes before passive leg raising, throughout the 10-minute maneuver, and for 5 minutes after return to the semi-recumbent position, resulting in six repeated 20-minute NIV periods during the study day. Ventilator settings: FiO2 21%, initial PEEP 5 cmH2O (adjustable down to 2 cmH2O for tolerance), and pressure support 0-5 cmH2O, titrated to avoid a tidal volume \>15 mL/kg predicted body weight (target 8-12 mL/kg).

Study summary

Passive leg raising (PLR) transiently increases venous return and cardiac preload and is commonly used to predict fluid responsiveness in critically ill patients. Repeated fluid boluses contribute to fluid overload in septic shock, whereas PLR may provide similar hemodynamic effects without fluid administration.

Before evaluating repeated PLR in septic shock patients, it is necessary to determine whether the cardiac output response to PLR remains present during repeated PLR maneuvers.

SYSLE-1 is a prospective interventional physiological crossover study conducted in healthy volunteers. Participants will undergo six consecutive passive leg raising sessions performed either during spontaneous breathing or non-invasive ventilation, in randomized order. The study aims to determine whether the increase in cardiac output induced by the first PLR maneuver persists during repeated PLR sessions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female participant. * Age 18 years or older. * Healthy volunteer without known acute or chronic disease. * No significant cardiovascular or respiratory disease. * No medication use within 10 days before the first study day (except oral contraceptives). * Intact upper and lower limbs. * Written informed consent. Exclusion Criteria: * Body mass index greater than 35 kg/m². * Use of illicit psychoactive substances within the previous 3 months. * Congenital or acquired absence of part or all of an upper or lower limb. * Known allergy to hydrocolloid dressings. * Pregnant or breastfeeding women. * Under guardianship, curatorship, or legal protection. * Deprived of liberty. * Not affiliated with a health insurance system. * Participation in another drug study during an exclusion period. * Member of the Lieu de Recherches Interventionnelles sur la Personne Humaine (LRIPH) or Intensive Care Unit staff. * Refusal to participate.

Primary outcome measure(s)

  • Change in cardiac output during the sixth passive leg raising session compared with the first passive leg raising session, for each day of study procedure — During study procedures on Days 1 and 2 (up to 10 days apart). From enrollment to the end of study (day 2) at 3 months maximum.
    Cardiac output measured every minute using thoracic bioreactance. The study will assess whether the increase in cardiac output during the sixth PLR session is non-inferior to 30% of the increase observed during the first PLR session.

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Régional d'Orléans Orléans Loiret
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07860515 on ClinicalTrials.gov ↗ ← All trials in France